Utopia Therapeutics, a biotech company developing vaccines for chronic metabolic diseases, has raised $1.5 million in a seed funding round from Whale Tank, an early-stage venture firm focused on breakthrough life science innovations.
The funds raised will be used to accelerate the preclinical development of UT009, Utopia’s lead immunotherapeutic candidate targeting obesity. UT009 is a novel vaccine designed to modulate the immune system to reduce fat accumulation and improve metabolic health by targeting lipid-associated antigens.
This investment will also support the advancement of UT009 toward regulatory toxicology studies, IND-enabling milestones, and Phase I human clinical trials.
Founded in 2024 by Uday Saxena and Gopi Kadiyala, Utopia Therapeutics is a biotech company that develops disruptive immunotherapies that address the root causes of chronic illnesses. To start with Utopia aims to deliver vaccines for obesity and related metabolic diseases using novel scientific approaches.
Uday Saxena and Gopi Kadiyala, founders of Utopia Therapeutics said, “We are thrilled to have Whale Tank as a strategic partner in our journey to redefine obesity treatment. Obesity is a global epidemic with limited long-term therapeutic options. UT009 represents a paradigm shift by differentiating it from current obesity drugs by address the root causes of weight gain. This investment enables us to move swiftly toward clinical translation.”
Markandeya Gorantla, Managing Partner, Whale Tank, said, “Utopia’s approach is bold, scientifically rigorous, and offers enormous potential to disrupt the obesity market. We are excited to support their mission of bringing Immunotherapeutics to the forefront of chronic disease management.”
